Whales with a lot of money to spend have taken a noticeably bullish stance on Viking Therapeutics.
Looking at options history for Viking Therapeutics VKTX we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 71% of the investors opened trades with bullish expectations and 21% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $146,590 and 10, calls, for a total amount of $1,709,969.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Viking Therapeutics during the past quarter.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Viking Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Viking Therapeutics's significant trades, within a strike price range of $35.0 to $100.0, over the past month.
Viking Therapeutics Call and Put Volume: 30-Day Overview
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | CALL | TRADE | BEARISH | 01/17/25 | $4.3 | $3.8 | $3.9 | $90.00 | $1.0M | 1.2K | 3.2K |
| VKTX | CALL | SWEEP | BULLISH | 11/15/24 | $10.2 | $9.9 | $10.2 | $60.00 | $203.9K | 6.0K | 206 |
| VKTX | CALL | SWEEP | BEARISH | 01/17/25 | $4.1 | $4.0 | $4.1 | $90.00 | $106.6K | 1.2K | 333 |
| VKTX | CALL | SWEEP | BULLISH | 12/20/24 | $10.3 | $10.0 | $10.3 | $62.50 | $102.9K | 0 | 101 |
| VKTX | CALL | TRADE | BULLISH | 11/15/24 | $5.4 | $5.1 | $5.3 | $70.00 | $53.0K | 8.4K | 407 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Viking Therapeutics
- Trading volume stands at 1,053,499, with VKTX's price down by -3.4%, positioned at $62.15.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 1 days.
Professional Analyst Ratings for Viking Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $114.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * In a cautious move, an analyst from Oppenheimer downgraded its rating to Outperform, setting a price target of $138. * In a cautious move, an analyst from HC Wainwright & Co. downgraded its rating to Buy, setting a price target of $90.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
